OCT 11, 2018 9:00 AM PDT

Discovering Cellular Mechanisms and Markers in Anti-PD1 Non-Responders Through Ingenuity Pathway Analysis and Oncoland

Sponsored by: QIAGEN
Speaker
  • Senior Field Application Scientist, QIAGEN Advanced Genomics
    Biography
      Devendra (Dev) received his PhD from University of California San Diego(UCSD) Biomedical Sciences graduate program and did postdoctoral studies under both academic and pharmaceutical settings. During his post-doctoral studies, he focused on cellular mechanisms regulating stem cells and cancer stem cells through next-gen sequencing data generation, analysis, interpretation and mining. Dev joined QIAGEN as a field application scientist in 2015. In the past 3 years, he has provided trainings to many pharma, biotech, academic and government investigators for different QIAGEN bioinformatics software. In addition, he has helped many of these users troubleshoot problems with their existing workflows and design new workflows.

    Abstract

    In the last two decades, large amount of next-generation sequencing (NGS) and -omics data has been generated in the field of immuno-oncology. Generating hypotheses by analyzing hundreds if not thousands of differentially expressed genes from expression studies and mining information from large amount of publicly available NGS and -omics data can be a very daunting task. QIAGEN’s Oncoland/Arraystudio (from Omicsoft) and Ingenuity Pathway Analysis (IPA) software provide with a set of tools and functionalities to do analysis and interpretation of NGS data to generate meaningful hypotheses and the ability to mine and compare information across a very large number of datasets curated from publicly available from sources such as GEO, SRA, TCGA, GTEX and others. In this webinar, we use gene expression data from a clinical study (GSE67501) focused on understanding the mechanism underlying anti-PD-1 therapy failure in advanced renal cell carcinoma patients. Using this data and the data curated from TCGA and other sources, it will be demonstrated how Arraystudio and Ingenuity Pathway Analysis can be used to generate hypotheses for mechanism of action and to discover potential targets and biomarkers.

    Learning Objectives: 

    1. Introduction to databases backing Ingenuity Pathway Analysis and Oncoland
    2. Studying potential biomarkers and targets through Oncoland’s data mining and comparison tools
    3. Generation of peer-reviewed literature backed hypotheses through Ingenuity Pathway Analysis


    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    Loading Comments...
    Show Resources
    Attendees
    • See more